Clinical trial · Interventional
Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients
NCT02751151CI-TRIAL-00054304PDTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will draw patients from the Transplant Dermatology specialty clinic, where the investigators see organ transplant recipients (OTR) for regular screening and serve as a regional referral center for this population. Enrollment will be limited to 20 patients. Inclusion criteria are organ transplant recipients status, active immunosuppression for at least 5 years, and history of at least one NMSC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nonmelanoma Skin Cancers | Skin Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| have Levulan Kerastick (aminolevulinic acid) solution | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
- interventionNames
- Other: have Levulan Kerastick (aminolevulinic acid) solution
Primary outcomes (1)
- measure
- Number of non melanoma skin cancers in organ transplant recipients
- timeFrame
- through study completion, an average of 2 years
Secondary outcomes (1)
- measure
- Reduction of actinic keratosis damage/epidermal dysplasia in organ transplant recipients as assessed by physician and graded per actinic damage scale
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient has been the recipient of any solid organ transplant. 2. Active immunosuppression for at least 5 years 3. History of at least one NMSC 4. Subject is willing to sign an informed consent to participate in this study. Exclusion Criteria: 1. Patient is not appropriate candidate for treatment or research trial per treating physician 2. Patient has a mental health condition that makes them unable to participate in this research trial, per PI judgment. 3. Patient is on additional immunosuppression for diagnosis unrelated to organ transplant -
References
Publications (0)
Data not yet available
No reference posted for this study.